Loading…
Minerva Neurosciences, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -69.6% over 5Y.
today you would have $244.25▼ -75.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $4.02 | $2.22 | $6.15 | $1.59 | $6.41 | $18.72 | $56.88 | $53.92 | $48.40 | $94.00 | $48.56 | $48.16 | |
| P/E | — | — | 11.7x | — | — | — | 46.8x | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ANTXAN2 Therapeutics, Inc. | $4.83 | — | 2.3x | — | -50.12% | $182.27M |
| HUMAHumacyte, Inc. | $0.65 | — | 12.5x | — | -547.87% | $180.6M |
| MENSJyong Biotech Ltd. | $2.37 | — | — | — | — | $180.19M |
| MSLESatellos Bioscience Inc. | $8.66 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/S | — | — | — | — | — | — | 2.4x | — | — | — | — | — | — |
| P/B | 3.0x | — | — | — | — | 4.3x | 1.9x | 10.0x | 2.9x | 1.8x | 3.9x | 3.0x | 2.9x |
| EPS | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.35 | $0.40 | -$14.80 | -$10.32 | -$6.64 | -$7.92 | -$9.28 | -$35.76 |
| Profit margin | — | — | — | — | — | — | 4.71% | — | — | — | — | — | — |
| ROE | -52.27% | — | — | — | — | -625.73% | 3.69% | -259.84% | -55.58% | -23.95% | -29.29% | -48.95% | -110.49% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.0x |
| — |
| -70.45% |
| $183.73M |
| XGNExagen Inc | $7.39 | — | 14.6x | — | -113.82% | $179.03M |
| ORGOOrganogenesis Holdings Inc. | $1.45 | — | 1.3x | — | -25.92% | $186.58M |